Merck, Moderna Melanoma Vaccine Study Succeeds

Merck and Moderna announced positive results from a late-stage trial of their personalized mRNA cancer vaccine for melanoma. The trial showed reduced recurrence of melanoma in patients who received the vaccine. The companies did not disclose specific efficacy numbers or trial size in the announcement.

Next story